Combination of R,R-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseases

US8048910B2 · kind B2 · utility

Assignee

• MEDA PHARMA GMBH & CO. KG · DE

Inventors

• Joachim Maus · Mühlheim, DE
• Horst Kastrup · Hachenburg, DE
• Istvan Szelenyi · Arnstorf, DE
• Peter Jurgen Cnota · Bad Homburg vor der Höhe, DE
• Artur Bauhofer · Marburg, DE

Key dates

• Filing date: Dec 21, 2006
• Grant date: Nov 1, 2011
• Expiry date: Nov 1, 2029

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/008
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel combinations based on anticholinergics, β2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases. A particular combination comprises R,R-glycopyrrolate, rolipram, and budesonide, or physiologically acceptable salts thereof, wherein dosage amounts are such that a synergistic therapeutic effect is achieved.